This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
Hamilton, Bermuda – December 20, 2017 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced on 7 December 2017 the company will be webcasting its corporate presentation at the BMO Capital Markets Healthcare Conference in New York, NY. The full filing stated:
DUBLIN, December 7, 2017 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the BMO
Capital Markets Healthcare Conference in New York, NY.
Matt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update at the
conference on Thursday, December 14, 2017 at 10:30 a.m. EST / 3:30 p.m. GMT.
A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.
Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to
the webcast.
An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at
www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and
commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in
the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase
Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and
Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.
Contacts:
Investors:
Kathee Littrell
Vice President, Investor Relations Jazz Pharmaceuticals plc
Ireland, +353 1 634 7887
U.S., +1 650 496 2717
Media:
Jacqueline Kirby
Vice President, Corporate Affairs & Government Relations Jazz Pharmaceuticals plc
Ireland, +353 1 697 2141
U.S., +1 215 867 4910